ClinicalTrials.gg
Active, not recruitingNCT07896915HS-20118-111Updated Oct 27, 2026

A Study to Evaluate the Pharmacokinetic Characteristics of HS-20118 Under Different Dosing Conditions in Healthy Participants

A Phase 1 interventional study of HS-20118 and HS-20118 in Healthy Participants, sponsored by Jiangsu Hansoh Pharmaceutical Co., Ltd.. Active, not recruiting at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-27.

Sponsored by Jiangsu Hansoh Pharmaceutical Co., Ltd. (part of Hansoh Pharmaceutical Group Company Limited) · Phase 1, Interventional, and Treatment

Updated Oct 27, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

This study is a single-center, open-label, randomized, four-period dosing clinical study designed to evaluate the pharmacokinetic characteristics of HS-20118 under different dosing conditions in healthy participants. It is planned to enroll 32 healthy participants.

Read the detailed description

This is a single-center, open-label, randomized, 4-period dosing clinical study. Eligible participants will be randomized into two groups: Group 1 and Group 2. A 42-day washout period will separate each consecutive period.

Dosing Conditions for Group 1:

Participants will be required to fast overnight for at least 10 hours prior to dosing across all 4 periods. In each period, a dose of 400 mg will be administered with approximately 180 mL of water. Water intake will be restricted from 2 hours pre-dose until 2 hours post-dose (except for the water used for dosing and beverages provided with the low-fat/high-fat meals). In Period 1, a low-fat meal will be consumed 1 hour post-dose; in Period 2, a low-fat meal will be consumed 30 minutes post-dose; in Period 3, a low-fat meal will be consumed 2 hours post-dose; and in Period 4, a high-fat meal will be consumed 30 minutes post-dose.

Dosing Conditions for Group 2:

In each period, a dose of 400 mg will be administered with approximately 180 mL of water, and water intake will be restricted from 2 hours pre-dose until 2 hours post-dose (except for the water used for dosing and beverages provided with the low-fat/high-fat meals).

Periods 1 to 3: Participants will fast for 6 hours prior to dosing in Periods 1 and 3, and for 4 hours prior to dosing in Period 2. Prior to the initiation of the pre-dose fast in each period, a low-fat meal must be completed within 15 minutes, following a fast of at least 4 hours before this meal. A low-fat meal will be consumed 2 hours post-dose in Periods 1 and 2, and 30 minutes post-dose in Period 3.

Period 4: Participants will fast for 6 hours prior to dosing. A high-fat meal must be completed within 30 minutes prior to the initiation of the pre-dose fast, following a fast of at least 4 hours before this meal. A high-fat meal will be consumed 30 minutes post-dose.

02

Conditions studied

  • Healthy Participants

Keywords

  • Phase I
  • Dosing Conditions
  • HS-20118
  • Healthy participants
03

In context

Lead sponsor

Jiangsu Hansoh Pharmaceutical Co., Ltd. is the lead sponsor of 138 studies on the registry; 72 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants fully understand the purpose, nature, methods, and potential adverse events of the study, participate voluntarily, and have signed the written form.
  2. Adult male and female participants aged 18 to 45 years (inclusive), on the date of signing the informed consent form.
  3. Body weight ≥ 50.0 kg for male participants, ≥ 45.0 kg for female participants, and ≤ 100.0 kg for both; (BMI) within the range of 18.0 to 26.0 kg/m2, inclusive.
  4. Agrees to have no procreative plans or plans for sperm/oocyte donation during the study and for 6 months after the last dose of study drug, and voluntarily agrees to use highly effective methods of .

Exclusion criteria

Exclusion Criteria:

  1. abnormalities in physical examination, vital signs, clinical laboratory tests, 12-lead (ECG), abdominal color Doppler ultrasound, chest X-ray, or CT scan during the screening period.
  2. Past history of, or current, serious diseases involving the neurological, psychiatric, gastrointestinal (digestive), cardiovascular (circulatory), respiratory, or urinary systems, or any new-onset illness prior to the administration of the product, which, in the opinion of the investigator, makes the participant unsuitable for participation in the study.
  3. Active infection (including chronic or localized infection) within 7 days prior to screening, history of recurrent infections with underlying diseases predisposing to infection, or history of opportunistic infections.
  4. Use of any prescription drugs, over-the-counter (OTC) drugs, herbal medicines, or health supplements (excluding topical preparations exerting localized effects) within 4 weeks or within 5 half-lives of the drug (whichever is longer) prior to the first dose.
  5. Receipt of any vaccine within 4 weeks prior to the first dose, or plan to receive any vaccine during the study.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    Group 1 (sequence1)

    Drug: HS-20118

  • Experimental
    Group 2 (sequence 2)

    Drug: HS-20118

Interventions

  • HS-20118 tablets will be administered orally as a single dose of 400 mg (two 200 mg tablets) with approximately 180 mL of water in each of the 4 treatment periods, separated by a washout period of at least 42 days. In each period, the drug will be administered under specific dietary and fasting conditions.

  • HS-20118 tablets will be administered orally as a single dose of 400 mg (two 200 mg tablets) with approximately 180 mL of water in each of the 4 treatment periods, separated by a washout period of at least 42 days. In each period, the drug will be administered under specific dietary and fasting conditions.

06

What researchers measure

Primary outcomes

  1. Cmax of HS-20118 under different administration conditions

    Time frame: Pre-dose up to Day 36 post-dose in Period 1, up to Day 78 in Period 2, up to Day 120 in Period 3, and up to Day 162 in Period 4

  2. Tmax of HS-20118 under different administration conditions

    Time frame: Pre-dose up to Day 36 post-dose in Period 1, up to Day 78 in Period 2, up to Day 120 in Period 3, and up to Day 162 in Period 4

  3. AUC0-t of HS-20118 under different administration conditions

    Time frame: Pre-dose up to Day 36 post-dose in Period 1, up to Day 78 in Period 2, up to Day 120 in Period 3, and up to Day 162 in Period 4

  4. AUC0-inf of HS-20118 under different administration conditions

    Time frame: Pre-dose up to Day 36 post-dose in Period 1, up to Day 78 in Period 2, up to Day 120 in Period 3, and up to Day 162 in Period 4

  5. t1/2 of HS-20118 under different administration conditions

    Time frame: Pre-dose up to Day 36 post-dose in Period 1, up to Day 78 in Period 2, up to Day 120 in Period 3, and up to Day 162 in Period 4

  6. CL/F of HS-20118 under different administration conditions

    Time frame: Pre-dose up to Day 36 post-dose in Period 1, up to Day 78 in Period 2, up to Day 120 in Period 3, and up to Day 162 in Period 4

  7. Vd/F of HS-20118 under different administration conditions

    Time frame: Pre-dose up to Day 36 post-dose in Period 1, up to Day 78 in Period 2, up to Day 120 in Period 3, and up to Day 162 in Period 4

Secondary outcomes

  1. Number of Participants with Adverse Events (AEs), Serious Adverse Events (SAEs), and Safety Abnormalities

    Incidence, seriousness, and severity of adverse events will be evaluated. Safety assessments will include vital signs, 12-lead electrocardiogram (ECG) parameters, physical examinations, and clinical laboratory tests.

    Time frame: Day 1 up to Day 183

  2. Incidence of Anti-drug antibody (ADA)

    Blood samples will be analyzed for the presence of ADAs against HS-20118

    Time frame: Pre-dose on Day 1 up to Day 162

07

Study locations

1 site
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2026 (actual). Primary completion is estimated for Dec 2026, 4 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 13, 2026
First posted
Oct 27, 2026
StartActual
Aug 3, 2026
Primary completionEst.
Dec 25, 2026
CompletionEst.
Dec 25, 2026
Last update
Oct 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 27, 2026
Show all 1 update
  1. Oct 27, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07896915
Responsible party
Sponsor
First posted
Oct 27, 2026
Start date
Aug 3, 2026
Primary completion
Dec 25, 2026 (estimated)
Completion
Dec 25, 2026 (estimated)
Last update
Oct 27, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HS-20118

Start the discussion